Gent, Belgium: October 23 2013 - Fujirebio Europe (previously Innogenetics), a leading international healthcare company that conceives, develops, produces and markets high quality in vitro diagnostics (IVD) testing solutions worldwide, will be presenting its LUMIPULSE® G1200, a fully automated chemiluminescent enzyme immunoassay (CLEIA) system, at the 10th Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL) Congress in the Internationales Congress Center Dresden, Germany, from October 23rd to 26th.
Press releases and announcements
Tokyo, Japan and Ghent, Belgium: October 1st, 2013 - Miraca Holdings Inc., a Japan-based holding company in the healthcare sector listed on the Tokyo Stock Exchange, today announced that its affiliate Innogenetics N.V. will change its name to Fujirebio Europe N.V. with immediate effect. The name change is the next logical step in an integration process that was launched by the acquisition in September 2010 of Innogenetics N.V. by Fujirebio Inc., a subsidiary of Miraca Holdings.
Ghent, Belgium: November 16, 2011 - Innogenetics, an international diagnostics company that develops and markets diagnostic products to improve therapy management and patient health, announced the Italian launch of its LUMIPULSE® G1200, a fully automated chemiluminescent enzyme immunoassay (CLEIA) system, at the 1° Congresso della Medicina di Laboratorio (SIMel/SIBioC) in Parma, Italy on November 16.
Tokyo, Japan: September 24 2010 – Fujirebio, a Miraca Holdings group company, has completed the acquisition of all of the issued and outstanding shares of Innogenetics NV. The acquisition was consummated in accordance with the terms and conditions of the definitive agreement that had been referred to in Fujirebio's previous release ("Fujirebio to acquire Innogenetics from Abbott") dated July 20, 2010.